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In this study, we examined the relationship between levels of lactoferrin (LF) and IL-17 in human serum and breast 
milk and the development of allergy in children. LF and IL-17 levels were determined by ELISA in healthy (n=19) 
and allergic mothers (n=21) on the 5th day after delivery. Two years later, information on breastfeeding and allergic 
outcomes was collected by questionnaires from parents of both groups and district child care nurses. Signifi cantly 
higher concentrations of LF were found in the breast milk of allergic mothers compared to the healthy controls. At 
2 years of age, only those three infants became allergic from the atopic group in whose starting breast milk samples 
a very high LF level (306 μg mg–1 protein) or simultaneously elevated concentrations of LF and IL-17 were 
measured. These fi ndings indicate that the very early measurement of LF and IL-17 levels in the breast milk of 
allergic mothers may help to predict the allergy development in their infants.
Keywords: allergy, atopy, breast milk, IL-17, lactoferrin, pollen allergy
There is a growing body of epidemiologic evidence supporting that maternal history of 
asthma predisposes offspring to atopic disorders more than paternal asthma (LITONJUA et al., 
1998; BOTTCHER & JENMALM, 2002; KURUKULAARATCHY et al., 2006). These observations can 
be explained by the fact that beside genetic factors originated from both parents, other 
maternal factors may play signifi cant role in the transmission of allergy susceptibility; 
however, these factors have not been fully elucidated (LIM et al., 2010). For example, this 
maternal effect may be based on the fact that mitochondria are inherited exclusively through 
maternal line, suggesting the contribution of mitochondrial genetic background to the 
pathogenesis of asthma. Indeed, a strong association was demonstrated between a common 
mitochondrial haplogroup and total serum IgE levels (RABY et al., 2007), and between the 
same mitochondrial haplogroup and the severity of allergic disease (ZIFA et al., 2012). On the 
other hand, while breast-feeding provides population-level protection from infections and 
atopy in infancy and early childhood (WILLS-KARP et al., 2004), it might also pose an increased 
risk of atopic asthma among children with asthmatic mothers (BOTTCHER & JENMALM, 2002). 
It is still unknown, which components of breast milk might be responsible for the various 
effects of breast milk in allergic and non-allergic mothers. Immunoglobulins, cytokines (e.g. 
IL-4, TGF-β1), chemokines (e.g. IL-8, RANTES), fatty acids, and leucocytes have all been 
suggested as potential candidates (JARVINEN & SUOMALAINEN, 2001).
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Recent studies have reported that serum IL-17 (CIPRANDI et al., 2008) and lactoferrin 
(LF) (CHOI et al., 2010) levels are strongly associated with the phenotypes of allergic rhinitis. 
Therefore, in this study, we investigated the associations between the serum and breast milk 
levels of these mediators and the development of allergy in infants.
1. Materials and methods
The study population comprised 19 healthy and 21 allergic mothers with verifi ed and 
confi rmed pollen allergy forming two groups matched in age, type of delivery, duration of 
breast feeding, and number of antibiotic treatments. The study was conducted in a pollen free 
season, when all patients were free of any allergic symptoms. Informed written consent was 
obtained from the mothers before the study. The study was approved by the Regional and 
Institutional Ethics Committee of the University of Debrecen.
Breast milk was collected from each mother by manual expression into sterile 
polypropylene containers on the 5th day after delivery at the Department of Gynecology at the 
University of Debrecen. To reduce potential diurnal variability in cytokine measurements, 
mothers were instructed to collect the milk samples in the early morning during the fi rst 
breastfeeding. Infants were allowed to suckle the nipple for a few minutes, and then a breast 
milk sample (3–6 ml) was taken and the feeding was continued. The milk samples were 
centrifuged in two consecutive steps to remove cells (2000 r.p.m., 10 min, room temperature) 
and fat (6000 r.p.m., 10 min, 4 °C) (RUDLOFF et al., 1999). Cell- and fat-free milk samples 
were transferred to the freezer and kept at –70 °C until analysis. On the same day, blood 
samples from mothers were drawn by venous puncture, were centrifuged. The sera were 
frozen and stored at –70 °C.
Two years later, information on breastfeeding, allergic outcomes, medication, and 
hospitalization was collected by questionnaires from parents and district child care nurses. 
The study groups’ information is summarized in Table 1.
LF (Calbiochem, Darmstadt, Germany) and IL-17 (R&D Systems, Minneapolis, MN, 
USA) levels in human serum and breast milk were determined by using ELISA according to 
the manufacturer’s instructions. Total protein concentration in breast milk samples was 
measured using COBAS Mira Plus (Roche Diagnostics, Basel, Switzerland) automated 
chemistry analyser.
For comparison of variables between two groups, the Mann-Whitney U-test or Student’s 
t-test was used. Data analysis was performed with SPSS version 12.0 for Windows (SPSS 
Inc. Chicago, IL, USA). Differences were considered to be statistically signifi cant at P<0.05.
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Table 1. Characteristics of the patient population
Characteristics Allergic mothers
(n=21)
Non-allergic mothers
(n=19)
P
Age of mother at delivery
Years, mean (SD)
29.8 (4.2) 28.9 (3.9) 0.511
Vaginal delivery / cesarean section
No. / no.
21 / 0 19 / 0 –
Season of breast milk collection
October – December, no. (%)
January – April, no. (%)
7 (33.3)
14 (66.7)
19 (100)
0 (0)
–
–
Duration of exclusive breastfeeding
Weeks, mean (range)
26.8 29.3 0.771
Antibiotic treatment during infancy
No. (%)
5 (23.8) 6 (31.6) 0.587
Allergic clinical symptoms during 
infancy
(until 2 years of age)
Allergic bronchitis, no.
Allergic dermatitis, no.
1
2
–
–
Breast milk total protein concentration
Mean (range), mg ml–1
24 (12.8–68.2) 24.5 (13.8–71) 0.911
Inclusion criteria for this study were (I) pregnancy and giving birth without any complications, (II) availability of 
completed questionnaire about allergic conditions, and (III) availability of blood and breast milk samples. Maternal 
atopy: self-reported seasonal rhinoconjunctivitis or pollen (Ambrosia artemisiifolia, Plantago lanceolata, Artemisia 
vulgaris, Solidago gigantea) allergy diagnosed by doctor/specialist.
2. Results and discussion
There was a great difference in the detection of LF and IL-17 in the sera and breast milk 
samples. Whereas LF occurred in a measurable concentration in each serum and milk sample 
(in 100%), IL-17 was detectable only in a much less rate in both types of samples (in a range 
of 5–19%). These data are shown in Table 2.
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Table 2. Detection of LF and IL-17 in serum and breast milk of allergic and non-allergic mothers (presented as 
percentage of number of samples)
Parameter Cut-off (pg ml–1) Serum Breast milk
Allergic% Non-allergic% Allergic% Non-allergic%
LF 1000 100 100 100 100
IL-17       4   10     5   19   11
The cut-off values were provided by the manufacturer or determined by adding three standard deviations to the mean 
optical density value of twenty zero standard replicates and calculating the corresponding concentration.
Although the levels of LF were markedly higher in the sera of allergic mothers as 
compared to those of non-allergic mothers, the differences were not statistically signifi cant 
(P=0.163). However, the LF concentrations were signifi cantly higher (P<0.05) in the breast 
milk (either expressed in mg ml–1 or μg mg–1 protein units) of allergic mothers. The amount 
of IL-17 was higher both in the serum (P=0.594) and breast milk (P=0.383) of allergic 
mothers, but these differences also were found statistically not signifi cant (Table 3).
Table 3. LF and IL-17 levels in the serum and breast milk of allergic (n=21) and non-allergic mothers (n=19)
Allergic mothers Non-allergic mothers P
Mean Median Range Mean Median Range
LF in the serum
(ng ml–1)
– 569.2 253.2–
2232.8
– 380 126.8–
346.8
0.163
LF in the milk
(mg ml–1)
3.36* – 2.02–4.31 2.88* – 1.32–4.88 0.037*
LF in the milk
(μg/mg protein)
– 171.75* 55.5–306 – 136.75* 49–191.5 0.032*
IL-17 in the serum
(pg ml–1)
– <4 <4–27.56 – <4 <4–4.88 0.594
IL-17 in the milk
(pg ml–1)
– <4 <4–47.94 – <4 <4–14.45 0.383
IL-17 in the milk
(pg mg–1 protein)
– 0.023 0.01–2.77 – 0.022 0.01–1.05 0.839
*: Signifi cantly different at P<0.05 level
At 2 years of age, none of the infants of non-atopic mothers showed allergic symptoms. 
On the other hand, the cumulative incidence of allergic disorders in the group of infants from 
atopic mothers was 14% (3/21). Table 1 demonstrates all LF and IL-17 data of the atopic 
mothers. When the associations of breast milk levels of LF and IL-17 with the development 
of allergic symptoms were further analysed, we found that each of the three atopic mothers 
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with allergic infants had higher level of LF in their breast milk than the mean of the allergic 
group (3.36 mg ml–1 versus 3.92, 4.17, and 306 mg ml–1). It was of a special note that in one 
of the atopic mothers, the concentration of breast milk reached the extra high level of 306 
mg ml–1 (without an increase in IL-17). However, the simultaneously elevated LF and IL-17 
levels could be detected exclusively in the milk of the two other atopic mothers.
Epidemiologic data suggest that rather the maternal than the paternal history of asthma 
confers a signifi cant risk for the development of allergy in infants (LIM et al., 2010). As an 
earlier study demonstrated lower serum LF levels in patients with allergy (CHOI et al., 2010), 
we expected in our study that the levels of LF would be lower in the breast milk of allergic 
mothers than in the healthy subjects. To our surprise, we have found that levels of LF were 
signifi cantly elevated in the breast milk of allergic mothers. Our results can be explained by 
the earlier systemic activation of peripheral blood phagocytes (neutrophils) still in the acute 
phase of seasonal allergic rhinoconjunctivitis prior/during pregnancy. Indeed, it was already 
described that a great amount of various infl ammatory mediators could be released during the 
active period of an allergic infl ammation even from a small area of the body (like 
rhinoconjunctivitis) causing a generalized and long-lasting activation of neutrophils 
(KALLENBACH et al., 1992; SZABÓ et al., 2000). LF released by activated neutrophils may 
mediate numerous compensatory effects to inhibit allergic infl ammations, decreasing mast 
cell degranulation, tryptase activity, eosinophils’ migration, and promoting the Th1-type 
immune responses (ELROD et al., 1997; HE et al. 2003; DE LA ROSA et al., 2008; BOURNAZOU et 
al., 2010). Our other fi nding, that IL-17 was more frequently detectable and its levels were 
higher (although not signifi cantly) both in the serum and breast milk of allergic mothers, 
supports the previous observation that some patients with pollen-induced allergic rhinitis 
may have high serum IL-17 levels outside of the pollen season (CIPRANDI et al., 2008). 
However, in our study, only those infants became allergic, whose mothers had a very high LF 
level (306 μg mg–1 proteins) or simultaneously elevated LF or IL-17 concentrations in the 
breast milk on the 5th day after delivery. Thus, these markers can be regarded as some kinds 
of predictive factors for allergy development in infants. In the three allergic mothers, the 
ability for the increased production of LF and IL-17 can be such a sensitive marker of a 
stronger atopic genetic background that has not only been effectively inherited by their 
children, thus owning a positive predictive value for early allergy, but it also separates them 
from those atopic mothers, who are lacking this capability. These observations, however, 
need further confi rmation in a larger study population in the future.
3. Conclusions
The early prediction of allergy in the newborns is one of the most important wish for atopic 
mothers and task for the paediatricians. This pilot study suggests that the demonstration of 
high levels of lactoferrin and/or IL-17 in the breast milk of mothers can be a useful approach.
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